Loading
A phase 2 trial of Eflapegrastim in non-Hodgkin lymphoma, run by Spectrum Pharmaceuticals, Inc, now recruiting.
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy is a phase 2 interventional study registered as NCT04570423 by Spectrum Pharmaceuticals, Inc, with 40 participants planned, started 2021-05-20 and due to reach its primary completion in 2027-10. Interventions recorded: Eflapegrastim and Chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Spectrum Pharmaceuticals and the tag pipeline.
Shares Spectrum Pharmaceuticals and the tag pipeline.
Shares Spectrum Pharmaceuticals and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/